Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Neuocrine and Sosei partner on schizophrenia drug

by Ryan Cross
November 26, 2021 | A version of this story appeared in Volume 99, Issue 43

Neurocrine Biosciences will pay Sosei Heptares $100 million to partner on developing small-molecule drugs for schizophrenia, dementia, and other neuropsychiatric disorders. Sosei’s compounds target specific muscarinic receptors and could have fewer side effects than drugs that target multiple receptors. Neurocrine plans a Phase 2 study next year of a selective M4 muscarinic receptor agonist for schizophrenia.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.